Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01425216 · ClinicalTrials.gov registry record · Phase 2
Sorafenib for Patients With Extensive Keloids
A Phase 2 study, sponsored by Tirgan, Michael H., M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01425216: Clinical Trial Phase 2 study, sponsored by Tirgan, Michael H., M.D..
NCT01425216 is a Phase 2 study that was terminated before completion, run by Tirgan, Michael H., M.D.. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01425216, a Phase 2 study, was terminated before completion, sponsored by Tirgan, Michael H., M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Treatment of keloid disorder is an area of unmet medical need. Current treatments for keloid partially address small and localized keloids, yet there are no wholly satisfactory or effective treatments for patients with extensive keloids. Such patients may benefit from effective systemic treatments. Sorafenib has the potential to regulate the three known dysregulated biological pathways in keloid tissue.
Primary Outcome
The primary objective of this trial is to demonstrate the efficacy of sorafenib in patients with extensive keloids.
Interventions
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Why NCT01425216 stopped before completion
NCT01425216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which Sorafenib is the first listed.
NCT01425216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01425216 about?
NCT01425216 is a clinical study titled "Sorafenib for Patients With Extensive Keloids". Treatment of keloid disorder is an area of unmet medical need. Current treatments for keloid partially address small and localized keloids, yet there are no wholly satisfactory or effective treatments for patients with extensive keloids. Such patients may benefit from effective systemic treatments. ...
What is the current status of trial NCT01425216?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2013-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01425216?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT01425216?
This trial is sponsored by Tirgan, Michael H., M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01425216's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia